AI assistant
GALECTIN THERAPEUTICS INC — Director's Dealing 2019
Sep 9, 2019
33422_dirs_2019-09-09_4c293013-1978-4c35-8616-a5fb84602c7f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2019-09-06
Reporting Person: FREEMAN KEVIN D (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-09-06 | Common Stock | P | 1290 | $3.71 | Acquired | 11000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 23469 | Direct |
| Common Stock | 16000 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were purchased in multiple transactions at prices ranging from $3.705 to $3.713 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by the Reporting Person at each separate price on each date of purchase.
F2: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.